Gubra aims to expand beyond obesity drugs, targets first portfolio partner this year

Copenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism.

The firm’s existing portfolio focuses on weight‑loss therapies, yet executives are actively exploring additional therapeutic areas to diversify their offerings.

Gubra’s leadership indicated that it hopes to secure its first external portfolio company partnership within the current year, signaling a strategic shift toward collaboration and expansion.

The move reflects the company’s ambition to transition from a single‑focus player to a more diversified biotech with multiple development programs.